| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | KIT; SCFR; Mast/stem cell growth factor receptor Kit; SCFR; Piebald trait protein; PBT; Proto-oncogene c-Kit; Tyrosine-protein kinase Kit; p145 c-kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CD antigen CD117 |
| Entrez GeneID | 3815 |
| WB Predicted band size | Calculated MW: 110 kDa; Observed MW: 120 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat,Monkey |
| Immunogen | The antiserum was produced against synthesized peptide derived from human c-Kit. AA range:688-737 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇关于c-Kit抗体的代表性文献，信息简明扼要：
1. **文献名称**：*Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors*
**作者**：Demetri GD, et al.
**摘要**：该研究验证了伊马替尼(靶向c-Kit受体的小分子抑制剂)在晚期胃肠道间质瘤(GIST)中的疗效，证实其通过抑制c-Kit激酶活性显著延长患者生存期，成为首个获批的c-Kit靶向疗法。
2. **文献名称**：*CD117: A Sensitive Marker for Gastrointestinal Stromal Tumors That Is More Specific Than CD34*
**作者**：Miettinen M, Lasota J.
**摘要**：研究证实抗c-Kit抗体(CD117)作为GIST诊断标志物的高敏感性和特异性，优于传统标志物CD34.为临床病理诊断提供了关键依据。
3. **文献名称**：*Resistance to C-Kit Inhibitors in Cancer: Mechanisms and Potential Solutions*
**作者**：Heinrich MC, et al.
**摘要**：探讨了肿瘤对c-Kit抑制剂(如伊马替尼)产生耐药性的分子机制，包括c-Kit二次突变及旁路信号激活，并提出联合用药策略以克服耐药问题。
4. **文献名称**：*A Novel Humanized c-Kit Antibody Induces Apoptosis in Myeloid Leukemia Cells*
**作者**：Wang Y, et al.
**摘要**：报道了一种新型人源化c-Kit抗体，可通过阻断配体结合并诱导c-Kit内吞降解，在急性髓系白血病模型中展现抗肿瘤活性，为血液肿瘤治疗提供新思路。
c-Kit antibodies target the c-Kit protein, a transmembrane receptor tyrosine kinase encoded by the *KIT* gene. Also known as CD117. c-Kit plays a critical role in cellular signaling pathways regulating cell proliferation, survival, and differentiation. It binds to stem cell factor (SCF), activating downstream signals like PI3K/AKT and MAPK/ERK. c-Kit is expressed in hematopoietic stem cells, mast cells, melanocytes, and interstitial cells of Cajal, making it vital for normal hematopoiesis, pigmentation, and gut motility.
Aberrant c-Kit signaling, due to mutations or overexpression, is linked to pathologies like gastrointestinal stromal tumors (GISTs), acute myeloid leukemia (AML), and mastocytosis. In GISTs, gain-of-function *KIT* mutations drive tumor growth, making c-Kit a key diagnostic marker (detected via immunohistochemistry) and therapeutic target. Tyrosine kinase inhibitors (e.g., imatinib) block c-Kit activity, but resistance mutations often arise, necessitating advanced inhibitors or antibody-based strategies.
c-Kit antibodies are widely used in research and diagnostics. Monoclonal antibodies (e.g., CD117 clones) enable precise detection of c-Kit expression in tissues or cells via flow cytometry, Western blotting, or immunohistochemistry. They also aid in isolating c-Kit-positive stem cells for regenerative studies. However, antibody specificity, epitope recognition differences between clones, and variable staining protocols require careful validation. Emerging therapies explore c-Kit antibodies for targeted drug delivery or as standalone biologics to inhibit oncogenic signaling, though clinical applications remain under investigation.
×
